This study investigated the mechanisms of salt resistance of four maize (Zea mays L.) hybrids [cultivar (cv.) Pioneer 3906 and newly developed hybrids SR03, SR12 and SR13] during the first phase of salt stress. Plants were grown in aerated nutrient solutions at 1 mM Na+ (control) and 100 mM Na+ (salt stress). Stress was imposed in 25 mM steps and plants were harvested after 2 days at 100 mM Na+. At 100 mM Na+ the area of the fourth leaf, which developed under salt stress, did not change significantly in SR03 and SR12 whereas significant reductions were observed in cv. Pioneer 3906 and SR13. Concentrations of assimilates (i.e. glucose, fructose and sucrose) in the shoot sap were significantly greater under salt stress in SR03 and SR12. However, the greater assimilate supply was not responsible for their salt resistance as there were no significant reductions in assimilate concentrations even in the other two genotypes. Shoot turgor and growth were maintained in SR03 and SR12 at 100 mM Na+ through significant increases in osmolality of the shoot sap. Concentrations of free ABA and ABA‐glucose esters (ABA‐GE) in the growing region of the fourth leaf increased significantly under salt stress in all genotypes. Leaf area at 100 mM Na+, expressed as a percentage of that at 1 mM, showed significant positive relationships with free ABA (R2 = 0.62) and the sum of free ABA and ABA‐GE (R2 = 0.65). Results of this study indicate clearly that a combination of partial osmotic adjustment, a possible reduction of the sensitivity of leaf growth under salt stress to increased ABA concentrations and a growth‐promoting function regulated by ABA is responsible for salt resistance in the first phase of salt stress. Genotypic variation in these mechanisms can be utilized to breed salt‐resistant genotypes in maize.

2004-02-01·Psychoneuroendocrinology2区 · 医学

Anticonvulsant efficiency, behavioral performance and cortisol levels: a comparison of carbamazepine (CBZ) and a fatty acid compound (SR-3)

2区 · 医学

Article

作者: Sharon Rabinovitz ; David I. Mostofsky ; Shlomo Yehuda

The role of fatty acids (FA) and their impact on nervous system activity and immune function has attracted much attention. The interest extends beyond a basic understanding of the potential role exerted by FA on the neuronal membrane and its properties, to the implications and clinical significance for many neurological disorders. This is especially true for epilepsy, where many conventional anticonvulsant preparations carry undesired side effects, and a significant number of patients remain refractory to the drug treatment. We report on a comparative examination in rats of carbamazepine (CBZ) and SR-3 (a fatty acid compound) with respect to seizure control efficiency, as well as protective features against cognitive impairment and cortisol level elevation. With pentylenetetrazol (PTZ) induced seizures pre-treated by CBZ, or SR-3, both CBZ and SR-3 were equally effective in providing seizure control and both were superior to the saline control. However SR-3 provided greater protection in Morris Water Maze performance and control of cortisol level elevation.

项与 SR-03 相关的新闻（医药）

2024-06-14

·BioSpace

Seraxis Wins Maryland Stem Cell Research Fund Grant to Accelerate Development of Allogenetically Compatible Pancreatic Islet Replacement Therapy for Functional Cure of T1D

$400,000 award will support characterization and efficacy testing of preclinical SR-03 cell line as a part of IND development. Seraxis is taking meetings at the American Diabetes Association Annual Meeting in Orlando, June 21-24. GERMANTOWN, MD / ACCESSWIRE / June 14, 2024 / Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, has been notified that the company is the awardee of a $400,000 Commercialization Program grant from the Maryland Stem Cell Research Fund (MSCRF) that aims to foster Maryland research to enhance and propel stem cell treatments. Seraxis will use the MSCRF grant to accelerate the validation and manufacturing of Seraxis' genetically modified pancreatic cell line (SR-03) that is designed to be a universal allogenic transplant that will not require lifelong anti-rejection immune suppression. Pancreatic Islet Replacement Therapies "Over 1.4 million Americans are Type 1 Diabetes patients burdened with daily glucose surveillance and exogenous insulin delivery to avoid glucose excursions and long-term organ damage," said Dr. William Rust, Ph.D., CEO of Seraxis. "MSCRF's grant funding will be key to advancing Seraxis' goal of establishing an immune-compatible allogenic pancreatic islet transplant therapy as a functional cure for people with insulin-requiring diabetes. SR-03 program is informed by SR-02, an islet replacement therapy requiring immune suppression that will enter the clinic by late 2024 for people with hypoglycemic unawares T1D." More information on SR-03 and SR-02 is available to potential pharma collaborators during the ADA annual meeting in Orlando next week. About Seraxis Seraxis is bringing transformative cures to the millions of people worldwide struggling with the management and life-threatening complications of T1D and insulin-requiring T2D. Seraxis' lead program, SR-02, is a novel, off-the-shelf islet replacement therapy slated to enter clinical testing with immunosuppressive therapy in 2024 in patients with severe recurrent hypoglycemia. A follow-on diabetes program, SR-03, is a version of the Seraxis pancreatic clusters altered to be unrecognized by the immune system for use without chronic immune suppression by the broader population of T1D and insulin-requiring T2D. Seraxis' underlying proprietary technology enables the creation of a pipeline of novel stem cell-derived therapies originating from single donated organs. The company's diabetes programs are manufactured from a stem cell line derived from a single highly compatible human donor's pancreas. These stem cells preferentially re-differentiate into pure pancreatic clusters containing all the endocrine cells of the native pancreatic islet, and with safety, potency, and manufacturing advantages over embryonic and induced pluripotent stem cells. Seraxis is backed by Frazier Life Sciences, Polaris Partners, Eli Lilly, the T1D Fund and independent investors. Seraxis manufactures its best-in-class therapeutic pancreatic clusters using scalable, clinically compliant processes in its cGMP facility located in Maryland's I-270 Biotech Corridor. Visit . About the Maryland Stem Cell Research Commission The Maryland Stem Cell Research Commission is focused on identifying and fostering cutting-edge research and innovation in the field of regenerative medicine in Maryland. Our Accelerating Cures initiative comprises programs that help transition human stem cell-based technologies from the bench to the bedside as well as mechanisms to build and grow stem cell companies in Maryland. Visit us at to learn more about our funding opportunities. Seraxis contact: Ted Hibben, Chief Corporate Development Officer: thibben@seraxis.com Contact Information Ted Hibben Chief Corporate Development Officer thibben@seraxis.com SOURCE: Seraxis, Inc. View the original press release on newswire.com.

细胞疗法临床研究免疫疗法

2024-01-04

·BioSpace

Seraxis' Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes

GMP-compliant manufacturing puts SR-02 on track to be industry's second clinical-stage stem cell derived pancreatic islet transplant program. The third-party auditor's FDA six-system approach yielded no critical nor major observations of Seraxis' quality system for the production of GMP-grade organs from pancreas-derived stem cells. Dr. William Rust, CEO, will present further data on the development of SR-02 and follow-on immune-cloaked SR-03 on Monday, January 8 at 10:30 a.m. PST at Biotech Showcase in San Francisco. GERMANTOWN, MD / ACCESSWIRE / January 4, 2024 / Seraxis, Inc., a regenerative medicine company developing a pancreatic islet replacement therapy to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, today announced the completion of a comprehensive third-party on-site Good Manufacturing Practice (GMP) audit of Seraxis' QMS, cleanroom, cell growing production process and QC laboratory, conducted in advance of Seraxis' planned IND submission of the pancreatic clusters candidate SR-02 for the intended treatment of insulin-dependent diabetes. The independent audit followed the FDA six-system approach and concluded that Seraxis' proprietary manufacturing process is in compliance with GMP audit standards, regulations and internal written procedures. "The manufacturing of an exquisite cluster of living cells - essentially the production of a replacement human organ - is a tremendously nuanced and intricate feat of biological engineering," said Seraxis' Chief Operating Officer, Carole Welsch, PhD. "We are proud that our team has created a clinical-scale cleanroom production facility and quality system that pass muster with a rigorous audit comparable to a possible future FDA inspection associated with our upcoming IND filings." "Seraxis' stem cell line SR1423 was derived from pancreatic cells and retains the epigenetic fingerprint of islets so, by design, they efficiently expand and generate replacement islet clusters. This characteristic eliminates purification steps, enabling Seraxis to manufacture product on a clinical scale for both the SR-02 program and the follow-on immune-cloaked SR-03 program in our Germantown facility," added CEO Will Rust. Dr. Rust will be presenting Seraxis' recent candidate development data in a presentation at Biotech Showcase on Monday, January 8, in a 10:30 a.m. (PST) session. The presentation will be posted to shortly thereafter. ABOUT SERAXIS Seraxis is bringing transformative cures to the millions of people worldwide struggling with the management and life-threatening complications of T1D and insulin-requiring T2D. Seraxis' lead program, SR-02, is a novel, off-the-shelf islet replacement therapy slated to enter clinical testing with immunosuppressive therapy in 2024 in patients with severe recurrent hypoglycemia. A follow-on diabetes program, SR-03, is a version of the Seraxis pancreatic clusters altered to be unrecognized by the immune system for use without chronic immune suppression by the broader population of T1D and insulin-requiring T2D. Seraxis' underlying proprietary technology enables the creation of a pipeline of novel stem cell-derived therapies originating from single donated organs for other indications. The company's lead therapeutic program, SR-02, is manufactured from a stem cell line derived from a human donor pancreas. These cells preferentially re-differentiate into pancreatic clusters containing all the endocrine cells of the native pancreatic islet, and with safety, potency, and manufacturing advantages over embryonic and induced pluripotent stem cells. Seraxis is backed by Frazier Life Sciences, Polaris Partners, Eli Lilly, the JDRF T1D Fund and independent investors. Seraxis manufactures its best-in-class therapeutic pancreatic clusters using scalable, clinically compliant processes in its cGMP facility located in Maryland's I-270 Biotech Corridor. For more information, please visit . Contact Information Ted Hibben Chief Corporate Development Officer thibben@seraxis.com SOURCE: Seraxis Inc. View the original press release on newswire.com.

临床研究细胞疗法

2023-10-26

·BioSpace

Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA

Manuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and in vivo function. Dr. William Rust, CEO of Seraxis, will deliver a lecture at the IPITA-IXA-CTRMS Joint Congress on October 29 at 10:00 a.m. in San Diego entitled "Novel stem cell-derived islet-like clusters potently control rodent blood glycemia". Seraxis will be taking meetings at BIO-Europe, November 6-8, in Munich. GERMANTOWN, MD / ACCESSWIRE / October 26, 2023 / Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, today announced the publication in bioRxiv of "Pancreatic Endocrine cell clusters derived from a non-pluripotent stem cell capable of regulating blood glucose in animal models of diabetes." The manuscript describes a novel population of stem cell-derived pancreatic endocrine cell clusters (SR-02) that form functional pancreatic grafts and potently regulate blood glucose levels in animal models. The SR-02 program is the subject of an upcoming IND filing for the treatment of severe recurrent hypoglycemia in patients with T1D. The unique nature of the SR-02 program and the company's clinical goals will be discussed by Dr. William Rust, CEO of Seraxis, at the International Pancreas & Islet Transplantation Association Congress on October 29 in San Diego, and further discussed by Ted Hibben, Chief Corporate Development Officer, at BIO-Europe, November 6-8, in Munich. Seraxis "This manuscript is the first description of a novel population of pancreatic endocrine cell clusters with the potential to be best-in-class as a practical cure for children and adults with insulin-requiring diabetes," said William Rust. ABOUT SERAXIS Seraxis is bringing transformative cures to the millions of people worldwide struggling with the management and life-threatening complications of T1D and insulin-requiring T2D. Seraxis' lead program, SR-02, is a novel, off-the-shelf islet replacement therapy slated to enter clinical testing with immunosuppressive therapy in 2024 in patients with severe recurrent hypoglycemia. A follow-on diabetes program, SR-03, is a version of the Seraxis pancreatic clusters altered to be unrecognized by the immune system for use by the broader population of T1D and insulin-requiring T2D without chronic immune suppression. Seraxis' underlying proprietary technology enables the creation of a pipeline of novel stem cell-derived therapies originating from single donated organs for other indications. The company's lead therapeutic program, SR-02, is manufactured from a stem cell line derived from a human donor pancreas. These cells preferentially re-differentiate into pancreatic clusters containing all the endocrine cells of the native pancreatic islet, and with safety, potency, and manufacturing advantages over embryonic and induced pluripotent stem cells. Seraxis is backed by Frazier Life Sciences, Polaris Partners, Eli Lilly, the JDRF T1D Fund and independent investors. Seraxis manufactures its best-in-class therapeutic pancreatic clusters using scalable, clinically compliant processes in its cGMP facility located in Maryland's I-270 Biotech Corridor. For more information, please visit . Contact Information Ted Hibben Chief Corporate Development Officer thibben@seraxis.com SOURCE: Seraxis Inc. View source version on accesswire.com:

细胞疗法临床研究

100 项与 SR-03 相关的药物交易

登录后查看更多信息